Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 10, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding increases in their personal holdings of Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than corporate financial performance.
Material Changes
The material change reported is an increase in share ownership by specific individuals following the re-investment of dividends paid on July 6, 2006. The transaction price was GBP 15.322 per Ordinary Share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a regulatory disclosure of insider trading activity compliant with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
Important Facts for Investors
- Transaction Type: Increase in share interests via dividend re-investment.
- Share Price: GBP 15.322 per Ordinary Share.
- Dividend Date: July 6, 2006.
- Notified Parties: Mr J Heslop (136 shares), Mr R Bondy (217 shares), Mr D Learmouth (27 shares), Dr D Pulman (117 shares), Mrs C Pulman (11 shares), Mr A Witty (18 shares), and Mrs C Witty (236 shares).
- Notification Date: July 7, 2006.